title: Use of rituximab in combination with high-dose methotrexate in the treatment of primary central nervous system lymphoma in a mycophenolate mofetil treated patient with lupus nephritis.
authors.forename: Gillianne Geet Yi
authors.initials: GG
authors.lastname: Lai
authors.forename: Yu Xuan
authors.initials: YX
authors.lastname: Koo
authors.forename: Miriam
authors.initials: M
authors.lastname: Tao
authors.forename: Thuan Tong
authors.initials: TT
authors.lastname: Tan
authors.forename: Soon-Thye
authors.initials: ST
authors.lastname: Lim
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D016470:Bacteremia / Q000276:immunology / Q000382:microbiology; D016543:Central Nervous System Neoplasms / Q000150:complications / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005334:Fever / Q000382:microbiology; D016469:Fungemia / Q000276:immunology / Q000382:microbiology; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008181:Lupus Nephritis / Q000150:complications / Q000188:drug therapy*; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D020258:Neurotoxicity Syndromes / Q000209:etiology; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D000069283:Rituximab; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab; D009173:Mycophenolic Acid; D008727:Methotrexate